| abstract |
The present invention relates to a cervical cancer-specific biomarker for the diagnosis of cervical cancer, and more specifically, to a method for providing information for the diagnosis of cervical cancer by detecting the methylation of a cervical cancer-specific biomarker in which a CpG island region of a specific gene in cervical cancer cells is specifically methylated. More specifically, if using a diagnostic kit and a nucleic acid chip for diagnosis, of the present invention, it is possible to diagnose cervical cancer in the initial transformation step, thereby enabling early diagnosis, and it is possible to predict the progress with respect to a high risk group, thereby enabling more accurate and rapid screening of cervical cancer compared with normal methods. |